Alcon Puts Money Where Mouth Is With Glaucoma Device Buy
This article was originally published in Scrip
Executive Summary
Barely a month after cutting its pharma portfolio and vowing to up investment in its surgical eye-care business, Novartis AG's Alcon has signed a deal that will bring a new micro-stent technology into its glaucoma portfolio.
You may also be interested in...
Glaukos Submits PMA For iStent, Second-Generation MIGS Device For Treating Glaucoma
Glaukos Corp. announced on Dec. 27 it has submitted a pre-market approval application to US FDA for its second-generation minimally invasive glaucoma surgery (MIGS) iStent device used for treating glaucoma, the second-leading cause of blindness.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.